Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. | 2001 Apr |
|
| [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. | 2001 May-Jun |
|
| Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. | 2002 Feb |
|
| [Selank and short peptides of Taftsin derivatives in regulation of adaptive behavior of animals in stress]. | 2002 Jun |
|
| [Optimizing action of synthetic peptide Selank on active avoidance conditioning test in rats]. | 2002 Sep-Oct |
|
| Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. | 2003 Nov |
|
| The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. | 2003 Sep |
|
| A new property of the synthetic anxiolytic Selank and its derivatives. | 2004 Jul-Aug |
|
| [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. | 2004 May-Jun |
|
| Seasonal effects of Selank on the behavior of hibernating animals. | 2005 Dec |
|
| [Effect of new synthetic anxiolytic selank on gastric wall blood flow and mesenteryc lymphatic vessels contractility in anesthetized rats]. | 2005 Feb |
|
| [Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats]. | 2005 Jul-Aug |
|
| [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. | 2006 Mar-Apr |
|
| [Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application]. | 2006 Mar-Apr |
|
| Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system. | 2006 Nov |
|
| [Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia]. | 2006 Nov |
|
| Selank and its metabolites maintain homeostasis in the gastric mucosa. | 2007 Jan |
|
| Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. | 2007 Nov |
|
| [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. | 2008 |
|
| [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. | 2008 |
|
| Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia. | 2008 Feb |
|
| Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. | 2008 Jul-Aug |
|
| [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]. | 2008 Mar-Apr |
|
| [Compensatory effect of selank on the mnestic functions disturbed by neurotoxic damage of the noradrenergic system of the rat brain]. | 2008 Mar-Apr |
|
| [Compensatory and antiamnestic effects of heptapeptide Selank in monkeys]. | 2008 May-Jun |
|
| [Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study]. | 2008 Sep-Oct |
|
| [Experimental hemorrhagic stroke: the study of neuropeptides (MIF, selank) in the intraperitoneal injection]. | 2009 |
|
| [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]. | 2009 Jul-Aug |
|
| [Antiviral activity of immunomodulator Selank in experimental influenza infection]. | 2009 Sep-Oct |
|
| [Experimental optimization of learning and memory processes by selank]. | 2010 Aug |
|
| Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank. | 2010 Jan-Feb |
|
| Antiviral properties of structural fragments of the peptide Selank. | 2010 Mar-Apr |
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 15:39:59 GMT 2023
by
admin
on
Sat Dec 16 15:39:59 GMT 2023
|
| Protein Type | PEPTIDE |
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
TS9JR8EP1G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SELANK
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | Selank is a synthetic analogue of the immunomodulatory peptide tuftsinas such, it mimics many of its effects. It has been shown to modulate the expression of Interleukin-6 (IL-6) and affect the balance of T helper cell cytokines. It has been shown to influence the concentration of monoamine neurotransmitters and induce metabolism of serotonin. Selank has also been found to rapidly elevate the expression of brain-derived neurotropic factor (BDNF) in the hippocampus of rats. | ||
|
TS9JR8EP1G
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
129954-34-3
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
SELANK
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
TS9JR8EP1G
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
2049928
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
11765600
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
DTXSID701029276
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Selank (sub-q and nasal) from Ceretropic: removed my anxiety/depression completely. I'm comfortable as who I am, but with out the drive to be better. I'm still my self. Just happier, nice, and more emotionally open. Socializing with friends and strangers is enjoyable again. Dosages/methods of administration: Iv used both nasal and sub-q over the past 6 or so months. the enhanced/nootropic, calm analytical effects only appear at around 600-750mcg via sub-q. anything below that (50-100mcg sub-q)that just takes the edge off, and removes anxiety.
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|